Alterity Therapeutics Limited

ATHE
$5.49 (- $0.40 - 6.79%)
Last updated: 2026-07-08 01:07 UTC
ATHE Metrics
Exchange
🇺🇸 NASDAQ XNCM
Nasdaq Capital MarketUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS02155X1063
CUSIP02155X106
Market Price5.49
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-0.56
Market Cap$57.5M
Book Value0.0
Price to Book944.155
Beta0.05
52w High7.0
52w Low2.52
Next Earnings DateN/A

Alterity Therapeutics Limited trades under ticker ATHE on NASDAQ as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US02155X1063, CUSIP 02155X106.

About the Company
Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434, a small molecule drug candidate that has completed Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; and ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy, as well as biomarkers of progression in multiple system atrophy. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is based in Melbourne, Australia.
Price History